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Methylphenidate use and school
performance among primary school
children: a descriptive study
Jurjen van der Schans1*, Rukiye Çiçek1, Sefike Vardar1, Jens HJ Bos1, Tjalling W de Vries2, Pieter J Hoekstra3
and Eelko Hak1,4
Abstract
Background: There is no conclusive evidence that stimulants have beneficial effects on major associated outcome
parameters, particularly school performance. We assessed the differences in school performance among children using
methylphenidate at the end of primary school in relation to various parameters of methylphenidate use.
Methods: We linked children from a pharmacy prescription database with standardized achievement test results at the
end of primary school. We explored differences in test scores between current methylphenidate users versus never
users and methylphenidate users who stopped treatment at least 6 months before the test, early versus late
starters, different dosage of methylphenidate, and concurrent antipsychotic or asthma treatment.
Results: Out of the 7736 children, 377 (4.9%) children were treated with methylphenidate at the time of the
test. After adjusting for confounders the methylphenidate users (532.58 ± .48) performed significantly lower
on the test than never users (534.72 ± .11). Compared with late starters of methylphenidate treatment (536.94 ± 1.51)
we found significantly lower test scores for the early starters (532.33 ± .50).
Conclusion: Our study indicates that children using methylphenidate still perform less at school compared to
their peers. Our study also suggests that earlier start of methylphenidate treatment is associated with a lower
school performance compared to children starting later with the treatment. This result could either indicate a
limited effect of long term treatment or a more strongly affected group of early starters.
Keywords: Methylphenidate, Attention-deficit/hyperactivity disorder, School performance, Pediatrics
Background
Attention-deficit/Hyperactivity disorder (ADHD) is the
most commonly diagnosed psychiatric disorder of child-
hood and is prevalent among approximately 3–5% of
school-aged children [1]. The negative impact of ADHD
on school performance is profound. Children with
ADHD have been shown to have lower grades, lower
mathematics and reading achievement scores, and a
higher rate of school dropout and grade retention [2–5].
Treatment of ADHD usually consists of a multi-model
approach in which combinations of pharmacological and
non-pharmacological options are being used. Besides the
non-pharmacological options like behavioral therapy (for
both child and parents), cognitive training, neurofeed-
back, psychoeducation, and dietary interventions [6],
stimulants are the first drug of choice in the manage-
ment of ADHD. In the Netherlands methylphenidate is
most frequently used [7]. In a recent systematic review
on the efficacy of methylphenidate the authors con-
cluded that methylphenidate might have a positive effect
on teacher-reported ADHD symptoms and teacher-
reported general behavior, but quality of the reviewed
studies was low and efficacy of psychostimulants was
questioned [8]. However, as stated in a commentary on
this study, the study’s methods has been criticized its
outcome heavily contradicts the wealth of available stud-
ies [9]. In general, most studies have concluded that the
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use of methylphenidate in children and adolescents with
ADHD also has a positive effect on school performance
when looking at different medication types of methylphen-
idate versus controls [10–13], and differences in adherence
[14]. These results were confirmed by the meta-analysis of
Prasad et al. in which the authors concluded that medica-
tion used in ADHD treatment could improve academic
achievement [15]. All in all, however, the long term effect-
iveness of stimulants on school performance remains un-
clear in spite of evidence of their short term efficacy in
relieving the core symptoms of ADHD and the positive
effect on school performance in controlled trial settings.
Moreover, it is questioned whether the efficacy of methyl-
phenidate on school performance holds in real-life treat-
ment settings, outside of formal trials, especially on the
long term. Therefore, population based studies, especially
focusing on long term effectiveness are warranted.
In this study we explored the differences in school per-
formance at the end of primary school between children
using methylphenidate and their peers. In addition, we
assessed differences in school performance among vari-




For this cohort study an analysis of the University of
Groningen IADB.nl pharmacy prescription database was
performed. The IADB database is a longitudinal pharmacy-
dispensing database with detailed patient-based drug pre-
scription data from 1994 till 2012 from approximately
600.000 patients in the Netherlands. Prescription rates
have been found to be representative of the Netherlands as
a whole, and the database has been widely used for re-
search [16]. Patient anonymity is guaranteed by the use of
an unique anonymous identifier, hence the ethical approval
for observational studies with data from the IADB has
been waived. Dutch patients usually register at a single
community pharmacy and therefore this pharmacy can
provide an almost complete listing of the subject’s pre-
scribed drugs [16].
Study population
Our study population consisted of 22,063 children born
between 1996 and 2001 (Fig. 1). By using a personal
identification number unique to every citizen, a linkage
with data from Statistics Netherlands (CBS) was per-
formed. Statistics Netherlands was responsible for per-
forming the linkage between the two datasets and
removed all identification information from the dataset,
hence researchers were unable to identify patients. The
final study population comprised all children whose full
data were available (n = 7736).
Outcome measure
In the Netherlands, all children at the end of primary
education around the age of 12 choose which type of
secondary education is the most appropriate for them.
At the end of primary school, the Central Institute for
Test Development (in Dutch: Cito-) test is performed
yearly in February in about 85% of the Dutch primary
schools [https://www.centraleeindtoetspo.nl/media/uplo
ads/files/cvte_tabellen_schaalscore_per_schooltype_en_br
ugklastype_2015.pdf]. The Cito-test score is a figure be-
tween 501 and 550, based on a transformation of the
number of correct answers for two hundred multiple
choice questions covering language, arithmetic/mathematic,
and general study skills. Because of this transformation we
were able to compare the scores from year to year despite
difference in difficulty of the tests. The score is an indicator
for the learning achievement of a child; indirectly it also is
an indicator for intelligence, motivation, concentration,
and drives to learn. For the reasons mentioned above the
Cito-test is used as an independent, standardized, educa-
tional achievement test which indicates the most suitable
type of secondary education(≤523: secondary education
leading to vocational education level 3; 524–528: level 2;
529–536: level 1; 537–544: secondary education leading to
higher professional education; ≥545 secondary education
leading to university).
Fig. 1 Flow chart of study population. Abbreviations: IADB, InterActive
DataBase; ADHD, Attention-Deficit/Hyperactivity Disorder;
MPH, Methylphenidate
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Methylphenidate exposure
Methylphenidate exposure was defined as having at least
one dispensed prescription for methylphenidate in the
period 2001 to 2012. We included children with a
follow-up period from the date of the first dispensing of
a prescription to at least the year the Cito-test was
taken. Children were only included in the study when
they were present in the database for at least 1 year be-
fore initiation of methylphenidate treatment. We ex-
cluded children with the date of the first dispensing of a
prescription after March in the year the Cito-test was
taken. In addition, children who took the Cito-test twice
were also excluded. Non-exposure (never users) was de-
fined as having no prescription of methylphenidate, and
no prescription of dexamphetamine or atomoxetine due
to their association with ADHD. The diagnostic status of
the children was not available.
Methylphenidate users
We considered children to have been treated on their
test day (February) if they had at least one dispensed
prescription for methylphenidate in the year the Cito-
test was taken from January 1st to March 31st. We de-
fined this treatment group as current users.
We compared current with past users, children who
have had at least one dispensed prescription of methyl-
phenidate but no prescription of methylphenidate in the
6 months before the Cito-test.
To estimate the influence of confounding by indication
we further assessed the association between school per-
formance and different patterns of methylphenidate use
by comparing early versus late start of treatment, current
versus past users, different dose regimens and co-
occurring conditions such as psychiatric disorders treated
with antipsychotics and atopic diseases which may all in-
fluence school performances [17]. Children with ADHD
are more commonly affected with atopic diseases like ec-
zema, asthma, and allergic rhinitis [18, 19].
Start of treatment
The start of treatment for each child was defined by the
date of the first dispensing of a prescription for methyl-
phenidate within the study period. We compared school
performance within the current users group according
to methylphenidate treatment start, e.g. early vs. late
start of treatment. We used February in the year of the
Cito-test as reference date and we defined starting the
treatment within 12 months (late start) and later than
12 months (early start) before this reference date.
Dosage of methylphenidate treatment
We compared school performance within the current
users group according to their different dosage of me-
thylphenidate treatment. The dosage was defined as the
number of Defined Daily Dose (NDDD) per day, which
we calculated by dividing the total number of DDD’s
prescribed for the drug by the theoretical number of
days the drug would be used. To compare different me-
thylphenidate dosage treatment groups we classified the
current users with prescriptions for methylphenidate in
different subgroups according to NDDD’s per day. Since
all children take the Cito tests around the same age we
assumed the dosage was not dependent on body weight,
but related to severity.
Concurrent treatment
We also considered concurrent drug use of other psy-
chotropic drugs. Concurrent drug use was defined as at
least 1 prescription for any psychotropic drug in the
year the Cito-test was taken from January 1st to March
31st in addition to at least 1 prescription for methyl-
phenidate in the same period. Other psychotropic drugs
were defined as all psychotropic drugs other than
methylphenidate.
In addition, we also sought to determine concurrent
use of medication for atopic diseases, i.e., inhaled corti-
costeroids, short acting beta agonists, nasal steroids, and
dermatological corticosteroids. Concurrent use of medi-
cation for atopic diseases was defined as having at least
2 prescriptions within a 12-month period in the year the
Cito-test was taken, in addition to having at least 1 pre-
scription from January 1st to March 31st.
Potential covariates
Demographic data on every child during the study
period, including sex, ethnicity, presence of single par-
enthood, and household income was obtained from the
CBS. We used data registered to 2012, which repre-
sented the most recent years of the IADB prescription
data available at the time of our study. We used the
household income data of the year 2011, which repre-
sents the halfway of the period in which the Cito-test
scores were available. Also, we used the type of house-
hold information of the year the Cito-test was taken. As
all children were 12 or 13 years old we did not include
birth year as a potential confounding factor.
We classified ethnicity as Dutch or non-Dutch, based
on the mother’s country of birth. Household income was
defined as the standardized disposable household in-
come in percentiles. We assigned household income to
subgroups according to household income as follows:
among the high-income group we considered the highest
20% household incomes. These households have an in-
come of at least 30,000 euros. The low-income group in-
cluded the lowest 40% household incomes with an income
around 18,550 euros. The intermediate-income group
considered the remaining 40% household incomes.
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Statistical analysis
The frequencies of the baseline characteristics were com-
pared by using Pearson chi-squared test. We also described
the characteristics of methylphenidate treatment, e.g. start
of treatment, dosage of treatment, and concurrent use of
antipsychotics or asthma medication. We described crude
mean Cito-test scores and tested for significance difference
with analysis of variance (ANOVA). Then we tested the
interaction terms between covariates and methylphenidate
exposure by using backward elimination to exclude non-
contributable confounding (p value > .05) from the predic-
tion model to measure whether the association between
methylphenidate use and Cito-test scores differed. An ana-
lysis of covariance (ANCOVA) was subsequently con-
ducted to test whether there was a statistically significant
difference in school performance measured by Cito-test
scores between the methylphenidate treatment groups after
controlling simultaneously for the effects of confounding.
Finally, we performed ANCOVA analyses to test for signifi-
cant differences in school performance between the
different treatment groups. In this study only children with
full data on all of the included variables were analyzed.
Cohen’s d was calculated to determine the standardized
difference between two means for the significant findings
(Cohen’s d ≥ 0.20; small difference; ≥0.50: moderate differ-
ence; ≥0.80 large difference). All analyses were conducted
using Statistical Package for Social Sciences (SPSS) version
22 and a two sided p value <0.05 was considered to be sta-
tistically significant.
Results
Characteristics between never users of methylphenidate
and current users during the time of Cito-test are shown
in Table 1. Baseline characteristics among our study
population varied for sex, ethnicity and household in-
come. Single parenthood was equally distributed over
the current and never users.
We only found sufficient numbers of medication users
with regard to antipsychotics in the other psychotropic
medication group, and asthma medication in the atopic
Table 1 Comparison of the characteristics between never users and current users
Never users, n (%) Current users, n (%) p value
(Chi2)
Total 7295 (100) 377 (100)
Sex <.05*
Boys 3275 (44.9) 298 (79.0)
Girls 4020 (55.1) 79 (21.0)
Ethnicity <.05*
Dutch 6407 (87.8) 358 (95.0)
non-Dutch 888 (12.2) 19 (5.0)
Parent Household .656
Two-parent household 5987 (82.1) 306 (81.2)
single-parent household 1308 (17.9) 71 (18.8)
Household income <.05*
low 3010 (41.3) 171 (45.4)
intermediate 3176 (43.5) 166 (44.0)
high 1109 (15.2) 40 (10.6)
Treated concurrently with
Asthma medication 100 (1.4) 11 (2.5) <.05*
Antipsychotics 19 (4.3)
Only MPH users 347 (78.7)
Start of MPH treatment
Late ≤12 months 38 (10.1)
Early >12 months 339 (89.9)
Dosage of MPH treatment
≤ 0.999 NDDD/Day 202 (53.6)
> 0.999 NDDD/Day 132 (35.0)
Abbreviations: n, sample size; NDDD, number of Defined Daily Dose
* Significant at .05 level
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medication group. Therefore we could only compare
concurrent use of antipsychotics with methylphenidate
use and concurrent use of asthma medication with me-
thylphenidate use.
Table 2 shows the baseline characteristics of the study
population and results of univariate analyses of the pos-
sible confounders in relation to Cito-test scores.
The difference in Cito-test scores between the house-
hold income categories tended to significance after ex-
cluding the non-significant interaction terms (p value .101
from.153).
Results of the crude and adjusted mean Cito-test scores
controlled for potential effects of sex, ethnicity, parent
household and household income are presented in Table 3.
After adjustments for the potential confounders, the
means of Cito-test scores still differed significantly be-
tween the current users and never users. The difference
in test score between groups corresponds to a 4% differ-
ence when taking into account the score range and a
small standardized difference between means (Cohen’s d
of 0.20). The adjusted mean estimates remained similar
to the crude mean Cito-test scores indicating limited in-
fluence of confounding.
In the second part of the table the comparison is made
between past and current users of methylphenidate. Both
crude and adjusted analyses show no significant difference
between both groups. All the covariates, sex, ethnicity,
parent household, and household income, had significant
influence on the outcome of the mean Cito-test scores.
When comparing the different dose regimens of me-
thylphenidate (≤0.999 & >0.999 NDDD/Day) no signifi-
cant difference was shown in both the crude and the
adjusted models.
Compared with late starters (536.94 ± 1.51) we found
significantly lower Cito-test scores for the early starters
(532.33 ± .50) with a small standardized difference be-
tween means of the crude data (Cohen’s d of 0.43). The
adjusted mean of the effect of start treatment on Cito-
test scores changed only minimally when we included
the covariates, indicating only negligible confounding by
these variables. The average Cito-test scores did not
differ significantly between early and late starters
among the covariates ethnicity and parent household.
The adjusted mean Cito-test scores reported remained
nearly the same when controlling simultaneously for all
covariates except for the methylphenidate + asthma
medication group. We found no significant differences
in Cito-test scores when comparing the different con-
current medication groups. Average Cito-test scores
differed significantly only among the covariate sex for
the concurrent treatment with antipsychotics.
Discussion
This study shows that methylphenidate users have a
lower school performance compared to children who
have no history of ADHD medication. Furthermore, our
results indicate that early starters of methylphenidate
treatment have significantly lower school performance
Table 2 Baseline characteristics of the study population and results of univariate analyses of the possible confounders in relation to
Cito-test scores
Never users M ± SD Current users M ± SD Subgroups p value interaction p value
Total 534.71 ± 9.47 532.80 ± 9.44 <0.001***
Sex .020*
Boys 535.25 ± 9.42 533.60 ± 9.26 0.004**
Girls 534.27 ± 9.49 529.75 ± 9.55 <0.001***
Ethnicity .296
Dutch 535.09 ± 9.33 532.82 ± 9.41 <0.001***
Non-Dutch 531.97 ± 10.0 532.37 ± 10.27 .86
Parent Household .762
Two-parent household 535.18 ± 9.40 533.20 ± 9.42 <0.001***
Single-parent household 532.55 ± 9.49 531.07 ± 9.42 .20
Household income .101
Low 532.31 ± 9.68 531.26 ± 9.21 .17
Intermediate 535.41 ± 9.11 533.70 ± 9.50 0.019*
High 539.20 ± 7.81 535.63 ± 9.27 0.005**
Treated concurrently with
Asthma medication 537.10 ± 8.52 535.64 ± 8.94 .591
Abbreviations: n, sample size; M, mean; SD, standard deviation
*Significant at .05 level**Significant at the 0.01 level
***Significant at the 0.001 level
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than children starting later with the treatment. Finally,
past treatment compared to current treatment of me-
thylphenidate, different dosage of methylphenidate and
concurrent treatment with antipsychotic or asthma
medication all appear to not be related to school
performance.
In line with the previously established association be-
tween ADHD and poor school performance we found
that children using methylphenidate had lower school
performance compared with those who never used me-
thylphenidate [2–5, 20]. This indicates that methylphenid-
ate treatment does not normalize school performance in
our study population, however, it may be questioned
whether the difference is clinically relevant which is
reflected by the small standardized differences between
school performances of the different treatment groups. To
what extent methylphenidate treatment may still have
contributed to improvement of school performance can-
not be concluded from our observational data given the
lack of a non-treated ADHD group. The absent associ-
ation between methylphenidate dosage and school per-
formance suggests no major effects. Grizenko et al.(2006)
found that children with ADHD and comorbid learning
disability tended to respond more poorly to methylphen-
idate [21]. It could be that normalization of school per-
formance only occurred in children without comorbid
learning disabilities and therefor lowered the result of our
analyses.In our study, we found that early starters of me-
thylphenidate treatment had significantly lower school
performance than children starting later with the treat-
ment. It may be important to emphasize that late starters
had a higher average Cito-test score than the national
average of the Netherlands, which is around 535 [http://
www.cito.nl/onderzoek%20en%20wetenschap/achtergrond
informatie/primair_speciaal_onderwijs/eindtoets_onderzo
ek_achtergrond]. When comparing early start of treat-
ment with late start of treatment, the short-term effects of
methylphenidate may explain these findings, whereas the
long-term effects seem less effective. This is in line with
existing studies that demonstrated the efficacy of short-
term stimulant treatment [22–24]. With the correction for
confounding factors it is not likely that we could be deal-
ing with a subgroup of highly intellectual children.
However, we cannot rule out bias due to different dis-
ease characteristics between children starting treatment
late and early. These differences may introduce bias to
Table 3 Crude and adjusted mean Cito-test scores for different methylphenidate treatment characteristics
1. MPH treatment School performance
Crude M ± SD Adjusteda M ± SE n p value
Current users 532.80 ± 9.44 532.58 ± .48 377 <0.001***
Never users 534.71 ± 9.47 534.72 ± .11 7295
2. Past versus current users School performance
Crude M ± SD Adjusteda M ± SE n p value
Current users (n = 377) 532.80 ± 9.44 532.58 ± .48 377 .470
Past users (n = 64) 531.52 ± 10.70 531.67 ± 1.15 64
3. Dosage of MPH treatment School performance
Crude M ± SD Adjusteda M ± SE n p value
≤ 0.999 NDDD/Day 533.17 ± 9.60 533.16 ± .66 202 .498
> 0.999 NDDD/Day 532.44 ± 9.28 532.45 ± .81 132
4. Start of MPH treatment School performance
Crude M ± SD Adjusteda M ± SE n p value
Late start ≤12 months 536.37 ± 8.62 536.94 ± 1.51 38 .004**
Early start >12 months 532.40 ± 9.46 532.33 ± .50 339
5. Concurrent treatment School performance
Crude M ± SD Adjusteda M ± SE n p value
Only MPH 532.72 ± 9.45 532.70 ± .497 347 .937
MPH + AP 532.47 ± 9.71 532.87 ± 2.13 19
Only asthma medication 537.10 ± 8.52 536.90 ± .865 100 .845
MPH + asthma medication 535.64 ± 8.94 537.49 ± 2.86 11
Abbreviations: M, mean; SD, standard deviation; SE, standard error; n; sample size*Significant at the .05 level
**Significant at the 0.01 level
***Significant at the 0.001 level
aAdjusted for sex, ethnicity, parent household, and household income
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comparison, i.e., confounding by indication. It might be
expected that children with severe symptoms and more
persistent school problems start treatment earlier than
those with less severe symptoms. With regard to the
subtypes of ADHD, children with hyperactive/impulsive
symptoms might be recognized and treated earlier than
those who have predominantly inattentive symptoms,
because the hyperactivity/impulsive behavior is more
disruptive in the classroom [17]. A previous study in
Iceland also investigated the difference in start of treat-
ment [17]. Although they reported a significantly lower
risk of decline in school performance between ages 9
and 12 with earlier start of stimulants. Within our study
the influence of treatment on school performance over
time could not be examined, as we looked at the per-
formance on one test.
Comparing current users and past users showed no
difference on school performance, which strengthens the
conclusion that methylphenidate treatment either is los-
ing its long-term effect or that the past users are a group
with less severe ADHD problems. Because there was no
difference measured in the different dosage of treatment
groups it is less likely that the early starters of methyl-
phenidate consist of children with more severe ADHD.
It is not likely that missing data of dosage information in
11.4% of the children affected these results, because the
missing data of the dosage information is caused by the
incorrect or missing registration of this information by
the pharmacist.
With respect to potential confounding by co-morbidities,
on which we also lack direct information, we attempted to
capture co-existing psychiatric disorders by accounting for
concurrent antipsychotic use.However, we were unable to
identify an association between school performance
and use of antipsychotics This is in line with other
studies [25, 26].
In addition, we investigated the difference in school
performance among children who were concurrently
treated with asthma medication and only asthma medi-
cation users. Again, no significant difference was found.
In the current study, we employed the unique setting
by linking dispensed prescription records with school re-
cords to assess the effect of methylphenidate use in
childhood on primary school performance. A strength of
this study was, that we measured drug use by using
pharmacy records. This minimized the risk of recall bias,
often associated with survey data, and selection bias as-
sociated with use of localized community data. Another
strong aspect is the possibility to track children over
time until the Cito-test was taken [16]. Furthermore, our
objective outcome measure was standardized test scores
and because of this we were able to compare the scores
from year to year despite differences in the difficulty of
the tests.
The study also had several limitations. The biggest
limitation is the fact that we were not able to take base-
line ADHD severity into account. It is not unreasonable
to assume that more severely affected children would
have been identified at earlier ages and therefore started
earlier on methylphenidate. In the absence of any con-
trols, it is impossible to know how these children would
have performed on the Cito-test had they not received
methylphenidate.
In addition, there was no information about the mag-
nitude of potential bias created by other possible medi-
cation use, family factors and additional school services,
which could have over- or underestimated the actual dif-
ference in overall school performance between methyl-
phenidate users and never users. Since the IADB.nl
database contains only records of dispensed medication
it is not possible to measure the actual medication use.
Non-adherence could have led to an overestimation of
the actual use of methylphenidate.
Finally, in this study we controlled for several con-
founders. Our data indicate that methylphenidate use
and school performance is somewhat different across
boys and girls. Boys performed better on Cito-test than
girls. Additionally, in the multivariable analysis the inter-
action between methylphenidate use and child’s sex was
significant. This is in line with existing studies, which re-
veal that boys are three to four times more likely than
girls to be diagnosed with ADHD based on studies of
community samples. In clinically referred samples the
sex differences is as high as five- to nine-fold [27–29].
We assume that methylphenidate use does not have sex-
specific effects on school performance and it is therefore
likely that ADHD plays a major role. The other possible
confounders, which we included in our multivariable
analysis, did not show significant effects.
In the subgroup analysis, it was remarkable that in both
the methylphenidate users and the never users group the
school performance was better as household income was
higher. On average, children with a high household in-
come scored nearly 7 point higher in the never users
group and approximately 4 points higher in the current
users group compared to the lowest income bracket. This
is consistent with a previous study that is also conducted
with Cito-test scores by researchers of the CBS. [http://
www.cbs.nl/en-GB/menu/themas/onderwijs/publicaties/ar
tikelen/archief/2013/2013-3815-wm.htm].
It should also be noted that there might be some un-
measured confounding as a result of our limitations.
Taking into account potential clustering of children
within schools and/or classrooms could have prevented
part of the unmeasured confounding, but such clustered
analysis was not possible because such identifying infor-
mation was for privacy reasons not available in the data-
base. Potentially, the severity of ADHD symptoms and
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comorbid learning disabilities could have influenced the
school performance. It is known from literature that
children with comorbid learning disabilities respond
poorer to stimulant treatment, and this should be taken
into account in a future study [21]. We also lack infor-
mation about non-pharmacological treatment like con-
current behavior therapy and additional school services.
However, from literature we know that concurrent be-
havioral therapy provides only modest advantages com-
pared with drug treatment alone [30]. Thus, this may
not be of major concern.
We suspect that children who received special educa-
tional services had better outcomes than children without
such services. In a further study this effect could be better
explored, while also taking into account the perspectives
of the teachers.
Although our study showed an association between
various parameters of methylphenidate use and school
performance, it must be noted that without a clear
comparator group and using only correlational data no
conclusions can be drawn about cause and effect of
methylphenidate use and school performance.
Importantly we need prospective, controlled and large-
scaled studies on the long term to evaluate whether
short term or chronic methylphenidate treatment will
improve school performance of children with ADHD.
Conclusion
In this retrospective descriptive study, earlier start of
methylphenidate treatment was associated with a lower
school performance than children starting later with the
treatment which could indicate a limited effect of long
term treatment or a more strongly affected group of
early starters. Our study also indicates that children
using methylphenidate still perform less at school com-
pared to their peers. More study is however warranted
to unravel why children who are methylphenidate
treated do not score similar as their peers, especially
when treatment starts early.
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